Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 12, 2012, Pages 6298-6303

  Vaes, M ^a   Hites, M ^b   Cotton, F ^b   Bourguignon, A M ^a   Csergo M ^a   Rasson, C ^a   Ameye, L ^a   Bron, D ^a   Jacobs, F ^b   Aoun, M ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIFUNGAL AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOSPORIN; POSACONAZOLE; PREALBUMIN; PROTON PUMP INHIBITOR; RANITIDINE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; FAT INTAKE; FEMALE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEPATIC CYTOLYSIS; HUMAN; LIVER CELL DAMAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SYSTEMIC MYCOSIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; SPECTROPHOTOMETRY, ULTRAVIOLET; TACROLIMUS; TRIAZOLES; YOUNG ADULT;

EID: 84869206302     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01177-12     Document Type: Article

References (25)

1. Alffenaar J-WC, van Assen S, van der Werf TS, Kosterink JGW, Uges DRA. 2009. Omeprazole significantly reduces posaconazole serum trough level. Clin. Infect. Dis. 48:839.
2. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34.
3. Conte JE, Jr, et al. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707.
4. Cornely OA, et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
5. Courtney R, Pai S, Laughlin M, Lim J, Batra V. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47:2788-2795.
6. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
7. De Pauw B, et al. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 46:1813-1821.
8. Ezzet F, et al. 2005. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet. 44:211-220.
9. Fleisher D, Li C, Zhou Y, Pao LH, Karim A. 1999. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin. Pharmacokinet. 36:233-254.
10. Gubbins PO, et al. 2006. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother. 50:1993-1999.
11. Kohl V, et al. 2010. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob. Agents Chemother. 54:207-212.
12. Krishna G, et al. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232.
13. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. 2007. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 27:1627-1636.
14. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
15. Lebeaux D, et al. 2009. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob. Agents Chemother. 53:5224-5229.
16. Mehta AK, Langston AA. 2009. Use of posaconazole in the treatment of invasive fungal infections. Expert Rev. Hematol. 2:619-630.
17. Michallet M, Ito JI. 2009. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J. Clin. Oncol. 27:3398-3409.
18. Nivoix Y, et al. 2008. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin. Infect. Dis. 47:1176-1184.
19. Sansone-Parsons A, et al. 2007. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27:825-834.
20. Sansone-Parsons A, et al. 2007. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 51:495-502.
21. Thompson GR, III, et al. 2009. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother. 53:2223-2224.
22. Ullmann AJ, et al. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666.
23. Ullmann AJ, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
24. Walsh TJ, et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
25. Wexler D, et al. 2004. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 21:645-653.